Literature DB >> 20436493

Assessing the risk of T-cell malignancies in mouse models of SCID-X1.

Brian Sorrentino1.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20436493      PMCID： PMC2890113          DOI： 10.1038/mt.2010.69

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  31 in total

Review 1.  Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency.

Authors:  Matthew P McCormack; Terence H Rabbitts
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245

2.  Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy.

Authors:  Annette Deichmann; Salima Hacein-Bey-Abina; Manfred Schmidt; Alexandrine Garrigue; Martijn H Brugman; Jingqiong Hu; Hanno Glimm; Gabor Gyapay; Bernard Prum; Christopher C Fraser; Nicolas Fischer; Kerstin Schwarzwaelder; Maria-Luise Siegler; Dick de Ridder; Karin Pike-Overzet; Steven J Howe; Adrian J Thrasher; Gerard Wagemaker; Ulrich Abel; Frank J T Staal; Eric Delabesse; Jean-Luc Villeval; Bruce Aronow; Christophe Hue; Claudia Prinz; Manuela Wissler; Chuck Klanke; Jean Weissenbach; Ian Alexander; Alain Fischer; Christof von Kalle; Marina Cavazzana-Calvo
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

3.  Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells.

Authors:  Boris Calmels; Cole Ferguson; Mikko O Laukkanen; Rima Adler; Marion Faulhaber; Hyeoung-Joon Kim; Stephanie Sellers; Peiman Hematti; Manfred Schmidt; Christof von Kalle; Keiko Akagi; Robert E Donahue; Cynthia E Dunbar
Journal:  Blood       Date:  2005-06-02       Impact factor: 22.113

4.  Gene therapy: therapeutic gene causing lymphoma.

Authors:  Niels-Bjarne Woods; Virginie Bottero; Manfred Schmidt; Christof von Kalle; Inder M Verma
Journal:  Nature       Date:  2006-04-27       Impact factor: 49.962

Review 5.  Genotoxicity of retroviral integration in hematopoietic cells.

Authors:  Arthur W Nienhuis; Cynthia E Dunbar; Brian P Sorrentino
Journal:  Mol Ther       Date:  2006-04-19       Impact factor: 11.454

6.  Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity.

Authors:  Ute Modlich; Jens Bohne; Manfred Schmidt; Christof von Kalle; Sabine Knöss; Axel Schambach; Christopher Baum
Journal:  Blood       Date:  2006-07-06       Impact factor: 22.113

7.  Importance of murine study design for testing toxicity of retroviral vectors in support of phase I trials.

Authors:  Elke Will; Jeff Bailey; Todd Schuesler; Ute Modlich; Brenden Balcik; Ben Burzynski; David Witte; Gerlinde Layh-Schmitt; Cornelia Rudolph; Brigitte Schlegelberger; Christof von Kalle; Christopher Baum; Brian P Sorrentino; Lars M Wagner; Patrick Kelly; Lilith Reeves; David A Williams
Journal:  Mol Ther       Date:  2007-02-13       Impact factor: 11.454

8.  Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy.

Authors:  Yan Shou; Zhijun Ma; Taihe Lu; Brian P Sorrentino
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-24       Impact factor: 11.205

9.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

Authors:  Marion G Ott; Manfred Schmidt; Kerstin Schwarzwaelder; Stefan Stein; Ulrich Siler; Ulrike Koehl; Hanno Glimm; Klaus Kühlcke; Andrea Schilz; Hana Kunkel; Sonja Naundorf; Andrea Brinkmann; Annette Deichmann; Marlene Fischer; Claudia Ball; Ingo Pilz; Cynthia Dunbar; Yang Du; Nancy A Jenkins; Neal G Copeland; Ursula Lüthi; Moustapha Hassan; Adrian J Thrasher; Dieter Hoelzer; Christof von Kalle; Reinhard Seger; Manuel Grez
Journal:  Nat Med       Date:  2006-04-02       Impact factor: 53.440

Review 10.  Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution.

Authors:  Rebecca H Buckley
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527
View more
  3 in total

1.  Lentiviral vector gene therapy: effective and safe?

Authors:  Derek A Persons
Journal:  Mol Ther       Date:  2010-05       Impact factor: 11.454

2.  Distribution of lentiviral vector integration sites in mice following therapeutic gene transfer to treat β-thalassemia.

Authors:  Keshet Ronen; Olivier Negre; Shannah Roth; Charlotte Colomb; Nirav Malani; Maria Denaro; Troy Brady; Floriane Fusil; Beatrix Gillet-Legrand; Kathleen Hehir; Yves Beuzard; Philippe Leboulch; Julian D Down; Emmanuel Payen; Frederic D Bushman
Journal:  Mol Ther       Date:  2011-03-08       Impact factor: 11.454

3.  Transduction of fetal mice with a feline lentiviral vector induces liver tumors which exhibit an E2F activation signature.

Authors:  Reba Condiotti; Daniel Goldenberg; Hilla Giladi; Temima Schnitzer-Perlman; Simon N Waddington; Suzanne Mk Buckley; Denise Heim; Wing Cheung; Matthew Themis; Charles Coutelle; Alina Simerzin; Emma Osejindu; Henning Wege; Michael Themis; Eithan Galun
Journal:  Mol Ther       Date:  2013-08-28       Impact factor: 11.454
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.